FDA says ad for Abbott’s Humira downplays risks

WASHINGTON (Reuters) - An advertisement for Abbott Laboratories’ Humira minimizes the arthritis drug’s risks while suggesting it can treat a wider range of patients than it is approved to treat, the U.S. Food and Drug Administration said in a letter released on Tuesday.

The drug is cleared to treat certain patients with arthritis, psoriasis, Crohn’s Disease or a form of arthritis called ankylosing spondylitis.

But the ad, used in a trade publication for doctors, “is misleading because it suggests that Humira is useful in a broader range of conditions or patients than has been demonstrated by substantial evidence or substantial clinical experience,” the FDA wrote in the December 16 letter to the drugmaker.

In the case of psoriasis, the drug is only approved for patients when other therapies fail, the FDA said. The ad “misleadingly suggests that Humira is approved for any patient with moderate to severe chronic plaque psoriasis,” it said.

Humira use is also linked to tuberculosis and other infections and includes a strong warning on its label.

In the ad, Abbott included the risk “in extremely small font size, and in single-spaced paragraph format that makes the information extremely difficult to read” while promoting its benefits with pictures and large text, the FDA said.

Abbott spokeswoman Michelle Johnson said the ad targeted doctors but ended in October. She could not say how long the ad was used.

The FDA, which stopped short of issuing a formal warning to the company, requested a reply from the drugmaker by January 2.

The FDA letter is on the agency’s website here

(Reporting by Susan Heavey)


Related Posts:

NEW YORK (Reuters Health) - The results of a new study suggest that patients with psoriatic arthritis, a form of rheumatoid arthritis accompanied by psoriasis, may have “subtle” cardiac conduction disturbances. Researchers point out, however, that it is not yet known if these irregularities lead to serious heart disease. “In surveying the literature, scant data were

Full Post: Abnormal ECG seen in psoriatic arthritis patients

NEW YORK (Reuters) - U.S. health regulators want longer-term data on the use of Merck & Co’s Gardasil cervical cancer vaccine in an older group of women before they will approve the vaccine for those women, the drugmaker said on Friday. The U.S. Food and Drug Administration has issued a second complete response letter to Merck

Full Post: More data sought for Merck’s Gardasil in older women

By Will Dunham WASHINGTON (Reuters) - About a quarter of biological medicines approved in the United States and Europe since 1995 have triggered safety warnings in the years after entering the market, Dutch researchers said on Tuesday. Immune system disorders, infusion reactions, infections and cancer concerns were among the reasons for safety warnings for biological medicines, which

Full Post: Many biological medicines draw safety warnings

By Susan Heavey WASHINGTON (Reuters) - Coca-Cola Co’s claims that its Diet Coke Plus include a variety of vitamins and minerals does not meet U.S. Food and Drug Administration’s standards, the agency said in a warning to the company. “The FDA does not consider it appropriate to fortify snack foods such as carbonated beverages,” the agency said

Full Post: FDA warns over Diet Coke Plus nutrition claims

WASHINGTON (Reuters) - U.S. health regulators have approved Novartis’ drug Gleevac to reduce the risk of cancer recurring in patients with a rare type of stomach cancer, Novartis said on Friday. Gleevac is already approved by the Food and Drug Administration to treat gastrointestinal stromal tumor, a severe type of cancer that recurs in as many

Full Post: U.S. OKs Novartis Gleevac to reduce recurring cancer

Site Navigation

Most Read



  • kinwrite.com@gmail.com